NeuroLife launches wearable neurotechnology platform for stroke and spinal cord rehabilitation

NeuroLife has launched as a non-invasive neurotechnology company developing wearable rehabilitation solutions for people recovering from stroke and spinal cord injury, alongside the completion of a $2.9 million seed funding round backed by founding partners Battelle and The NeuroTech Institute (NTI).

The company is introducing a wearable sleeve designed to support hand and arm rehabilitation by reading electrical signals from muscles and nerves, interpreting a user’s intended movement, and delivering targeted electrical stimulation during guided therapy.

Stroke and spinal cord injury continue to affect millions of people worldwide. In the United States alone, there are an estimated 7.8 million stroke survivors, according to the Centers for Disease Control and Prevention. While rehabilitation remains essential for recovery, many patients have limited access to intensive, personalized therapy.

NeuroLife says its platform is intended to help address this challenge through a wearable system that combines high-density neuromuscular sensing, intelligent signal decoding, and adaptive stimulation. By translating neuromuscular signals into real-time feedback, the technology is designed to support more personalized rehabilitation and functional recovery of the hand and arm.

“NeuroLife represents a focused step forward in how rehabilitation can evolve,” said Jon Snyder, CEO of NeuroLife.

“Our goal is to develop a non-invasive platform that supports functional hand and arm use by making therapy more personalized, responsive and aligned with how the body naturally moves.”

Designed as a flexible platform, the technology could also support future applications in neuromuscular analytics and other neuro-enabled solutions, in addition to rehabilitation.

Funding supports clinical validation and regulatory pathway

NeuroLife was established through a strategic partnership between Battelle and NTI, with Battelle licensing the underlying NeuroLife platform technology to the new company.

“Battelle has a long history of translating scientific innovation into real-world impact,” said Matt McFarland, Vice President of Commercial Strategy at Battelle.

“Our collaboration with NTI and the formation of NeuroLife advances neurotechnology from foundational research into clinical and commercial development. NeuroLife brings the rigor of Battelle’s research capabilities into a platform built for clinical environments and patient impact.”

The company’s $2.9 million seed financing will support the next stage of development as NeuroLife works toward FDA clearance for its wearable platform. Its roadmap includes clinical validation, regulatory progression, and preparations for commercial scale.

Alongside product development, NeuroLife is seeking collaborations with medtech companies, digital health organizations, and clinical research partners to support co-development, pilot programmes, and future commercialization.

Source

Battelle

Up next: MedTech World Asia 2026

For those looking to stay connected with developments across the Asia Pacific MedTech sector, MedTech World Asia 2026 will take place in Hong Kong from 26 to 28 August 2026. The event will bring together stakeholders from across the healthcare and medical technology community, offering a platform to exchange ideas, explore emerging trends, and strengthen connections across the region. Have a look at the agenda and secure your place now.

Ways to participate in MedTech World Asia

• Speak
• Present
• Partner
• Active Investor? Apply for your investor pass